Screener
Janux Therapeutics JANX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's EPS (diluted)?
- Janux Therapeutics (JANX) reported EPS (diluted) of -$0.35 in Q2 2026.
- How has Janux Therapeutics's EPS (diluted) changed year-over-year?
- Janux Therapeutics's EPS (diluted) increased by 36.4% year-over-year, from -$0.55 to -$0.35.
- What is the long-term trend for Janux Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Janux Therapeutics's EPS (diluted) has grown at a -13.2% compound annual growth rate (CAGR), from -$3.23 to -$1.83.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Janux Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude